Methylene Blue is NOT Recommended for Mental Health or Kidney Health
Methylene blue should not be used for mental health or kidney health purposes outside of its FDA-approved indication for treating acute methemoglobinemia, and it must be used with extreme caution in patients with renal impairment.
Critical Safety Concerns
Renal Impairment
The FDA drug label explicitly states that methylene blue should be used cautiously in patients with renal failure 1. The evidence shows:
- Methylene blue concentrations increase significantly in patients with renal impairment (eGFR 15-89 mL/min/1.73 m²) 1
- Dose adjustment is required for moderate to severe renal impairment (eGFR 15-59 mL/min/1.73 m²) 1
- The drug is substantially excreted by the kidney, increasing risk of adverse reactions in impaired renal function 1
While one animal study 2 and one small human study 3 showed potential protective effects against acute kidney injury, these were in specific contexts (ischemia-reperfusion injury and septic shock) and do not support general use for "kidney health."
Mental Health Concerns
The risk-benefit profile for mental health use is unfavorable:
Serious Drug Interactions
Methylene blue acts as a potent monoamine oxidase inhibitor and can precipitate serotonin syndrome when combined with:
- SSRIs (selective serotonin reuptake inhibitors)
- SNRIs (serotonin-norepinephrine reuptake inhibitors)
- MAOIs
- Bupropion, buspirone, clomipramine, mirtazapine
- Opioids and dextromethorphan 4, 1
This interaction can be potentially fatal 1.
Limited and Outdated Evidence
The research evidence for mental health benefits is weak:
- One small 1987 trial (15 mg/day) showed antidepressant effects 5, but this is nearly 40 years old with no modern replication
- A 2019 review 6 describes "promise" but acknowledges the need for caution due to MAO-A inhibition
- Animal studies 7 show neuroprotective effects but cannot be extrapolated to clinical practice
The FDA has not approved methylene blue for any psychiatric indication 1.
FDA-Approved Use Only
Methylene blue is approved exclusively for treating acquired methemoglobinemia at doses of 1-2 mg/kg IV 1. The 2021 American Journal of Hematology guidelines confirm this narrow indication 4.
Additional Safety Warnings
Beyond renal and psychiatric concerns:
- Hemolytic anemia risk in G6PD deficiency patients 4
- Teratogenicity concerns in pregnancy 1
- Hepatic metabolism requires monitoring in liver impairment 1
- Can cause confusion, dizziness, and vision disturbances affecting ability to drive 1
Clinical Bottom Line
Do not prescribe methylene blue for mental health or kidney health. If a patient is taking serotonergic medications (extremely common in mental health treatment), methylene blue is contraindicated due to serotonin syndrome risk. In patients with renal impairment, the drug accumulates and poses increased toxicity risk. The limited, outdated research on psychiatric benefits does not justify the serious safety risks, and no regulatory body has approved this use.
For mental health conditions, use evidence-based, FDA-approved treatments. For kidney health, address underlying causes with established nephroprotective strategies rather than experimental off-label use of a potentially harmful agent.